Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
bristol-myers squibb
clinical trials
gilead sciences
life sciences
national blog main
national top stories
new york blog main
new york top stories
nonalcoholic steatohepatitis
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
abbvie
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alez azar
allergan
alzheimer's disease
antibiotics
axial spondyloarthritis
bausch health
biogen
biotech
boston university
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
car-t immunotherapy
cell therapy
clinical data
cluster headache
crispr
deals
detroit blog main
What
drug
nash
2
×
new
2
×
approval
approved
bio
biogen’s
biopharmaceutical
companies
convo
data
disease
earlier
failures
fatty
horizon
intercept
known
littered
liver
marketed
medicine
news
nonalcoholic
price
remains
road
roundup
steatohepatitis
strategy
talk
track
Language
Current search:
nash
×
new
×
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
